Idiopathic pulmonary fibrosis (IPF) is a progressive fibrotic lung disease of unknown etiology
and dismal prognosis. IPF patients are known to have an increased risk of lung cancer and …

We have previously reported the antifibrotic effects of pirfenidone (PD) in the bleomycin (BL)-
hamster model of lung fibrosis. Since the development of fibrosis is generally preceded by …

Idiopathic pulmonary fibrosis (IPF) is a chronic and usually progressive lung disorder of
unknown aetiology. Conventional management of patients with IPF has been primarily …

Pirfenidone (PFD) slows the progression of idiopathic pulmonary fibrosis (IPF) by inhibiting
the exaggerated fibrotic response and possibly through additional mechanisms, such as anti …

Idiopathic pulmonary fibrosis (IPF) is a progressive fibrotic lung disease with an appalling
prognosis. The failure of anti-inflammatory therapies coupled with the observation that …

Transforming growth factor-β1 (TGFβ1) is the key profibrotic cytokine in idiopathic pulmonary
fibrosis (IPF), but the primary source of this cytokine in this disease is unknown. Platelets …

Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive, and usually fatal pulmonary
disease for which there are no proven drug therapies. Anti-inflammatory and …

1. Schaefer CJ, Ruhrmund DW, Pan L, Seiwert SD, Kossen K. Antifibrotic activities of
pirfenidone in animal models. Eur Respir Rev 2011; 20: 85‑97. 2. Udwadia ZF, Mullerpattan …

Fibroblast–myofibroblast differentiation (FMD) is a critical cellular phenotype during the
occurrence and deterioration of pulmonary fibrosis (PF). FMD can increase with an elevated …

Idiopathic pulmonary fibrosis (IPF) is the most common and lethal form of idiopathic
interstitial pneumonia. The disease, which occurs primarily in middle-aged and older adults …